Beijing SL Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mingbo Xu
Chief executive officer
CN¥385.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 22.6% |
| Management average tenure | no data |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Beijing SL Pharmaceutical (SZSE:002038) Is Increasing Its Dividend To CN¥0.15
Jul 02
Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) Popularity With Investors Is Under Threat From Overpricing
Jun 25Why Beijing SL Pharmaceutical's (SZSE:002038) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 30Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) 25% Price Boost Is Out Of Tune With Earnings
Mar 06CEO
Mingbo Xu (60 yo)
no data
Tenure
CN¥385,000
Compensation
Dr. Mingbo Xu founded Beijing SL Pharmaceutical Co., Ltd. in December 1994 and serves as its Chairman and General Manager. He served as President at Beijing SL Pharmaceutical Co., Ltd.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | CN¥385.00k | 22.62% CN¥ 1.9b | |
| Secretary & Non-Independent Director | no data | CN¥526.40k | 0.15% CN¥ 12.0m | |
| Non Independent Director | no data | CN¥50.00k | no data | |
| Supervisor | 3.6yrs | no data | 0.00052% CN¥ 42.6k | |
| Non-Independent Director | 9.6yrs | no data | no data | |
| Chairman of the Supervisory Board | 9.6yrs | no data | 0.00029% CN¥ 23.8k | |
| Independent Director | 3.6yrs | CN¥50.00k | no data | |
| Independent Director | 3.6yrs | CN¥50.00k | no data | |
| Non-Employee Supervisor | less than a year | no data | no data |
3.6yrs
Average Tenure
58yo
Average Age
Experienced Board: 002038's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 11:17 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing SL Pharmaceutical Co., Ltd. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| YANG QIAO | Changjiang Securities Co. LTD. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |